The Vaccine Industry Committee (VIC) hosted the second Vaccine Innovation Conference on May 10 at the Hyatt Regency in Montréal, Quebec. The Conference’s Scientific Steering Committee assembled international keynote speakers and over 100 Canadian representatives. The one day conference included academic, industry and government leaders focusing on vaccine innovation in Canada and delivered improved knowledge exchange and awareness of Canadian vaccine innovations and accomplishments and supported investment for vaccine R&D. Speakers included international renowned researchers from England (Dr. Adian Hill, Oxford University), the United States (Dr. Howard Kaufman, Rutgers University) and Norway (Dr. Bjørg Nilsson, Coalition for Epidemic Preparedness Innovations, CEPI). This year’s conference also featured a Canadian focused funding panel for vaccine R&D that included panelists from government, industry, venture capital and international funding organizations (CIHR, Teralys Capital, Merck and CEPI). The Vaccine Innovation Conference was held in conjunction with the Canadian Society for Pharmaceutical Sciences annual conference (CSPS), May 10-13, 2017.
Adrian V.S. Hill is Professor of Human Genetics and Director of the Jenner Institute at Oxford University. He leads research programmes in both the genetics of susceptibility to tropical infectious diseases and in vaccine development. The Jenner Institute links human vaccine research at the University of Oxford with veterinary vaccine development at The Pirbright Institute and the UK Animal and Plant Health Agency.
Dr. Howard L. Kaufman has been a leading authority on tumor immunotherapy for the treatment of melanoma. He pioneered the development of recombinant viral vectors encoding eukaryotic tumor antigens and immune modulatory genes for cancer therapy and has conducted over 50 cancer vaccine and immunotherapy clinical trials. Dr. Kaufman has maintained an NIH-funded laboratory in tumor immunology for over 15 years.